Top Stories

Grid List

InDex Pharmaceuticals Holding AB announced that the US FDA has granted orphan-drug designation for the drug candidate cobitolimod for treatment of ulcerative colitis in pediatric patients.

Recipharm, the contract development and manufacturing organisation (CDMO), and LIDDS have together set up a manufacturing line for LIDDS’ novel prostate cancer drug, Liproca® Depot, at Recipharm in Solna, Sweden.

Epidemiologists conducting national precision medicine initiatives focused on gathering clinical research data on genetic variation among East and South Asian populations now have access to Thermo Fisher Scientific's Applied Biosystems Axiom Asia Precision Medicine Research Array.

BioSight, Ltd, a pharmaceutical development company, focused on the development of targeted oncology therapeutics with reduced toxicity, announced completion of last patient treatment in its extended Phase I/II clinical study of BST-236 (Astarabine) in acute leukemia patients.

Kite Pharma, Inc , a leading cell therapy company announced that patients with relapsed/refractory indolent B-cell non-Hodgkin lymphoma (iNHL) are now being treated in its Phase 2 ZUMA-5 trial with its lead investigational candidate, axicabtagene ciloleucel (axi-cel).

Acasti Pharma Inc announced the achievement of a major corporate milestone by manufacturing the first cGMP batches of CaPre®, Acasti’s omega-3 pharmaceutical product candidate, produced with a proprietary and innovative continuous manufacturing process developed in partnership with CordenPharma.

Sartorius Stedim Biotech (SSB), a leading international supplier to the biopharmaceutical industry announced an agreement with Nova Biomedical (Nova), a well-known US manufacturer of cell culture analyzers, to integrate their BioProfile® FLEX2 into the ambr® multi-parallel bioreactor systems for automated, at-line cell culture analytics.

Contract development and manufacturing organisation (CDMO) Saneca Pharma has been granted a multiple dosage form approval for the manufacture and supply of solids, semi-solids and liquid finish dose products to Russia.

Manufacturers require high code accuracy and legibility from their Thermal Transfer Overprinters to improve production line efficiency and reduce overall costs.

With the recent increase in health consciousness globally, the concept of "farm to fork" has swept the world. As a result of this, the search for methods to reduce food loss and waste in the supply chain from the farm to the dining table, has becomea critical problem to solve; from the perspectives of both economics and environmental protection.

A Spanish contract development and manufacturing organisation (CDMO) has expanded its GMP manufacturing offering with the installation of new automatic capsule filling capabilities at its EU-GMP approved plant in Pamplona, Spain.

Market Movers

Rogers Corporation

NYQ : ROG - 18 Aug, 4:02pm
+0.24 (+0.21%) After Hours:
Open 113.96 Mktcap 2.09B
High 116.18 52wk Hight 123.38
Low 112.30 52wk Low 51.98
Vol 124453 Avg Vol 120777
Eps 5.55 P/e 27.77
Currency: USD

Banco Santander, S.A. Sponsored

NYQ : SAN - 18 Aug, 4:04pm
+0.08 (+1.25%) After Hours:
Open 6.40 Mktcap 99.36B
High 6.49 52wk Hight 6.99
Low 6.38 52wk Low 4.10
Vol 4.27M Avg Vol 7.01M
Eps 0.49 P/e 12.14
Currency: USD

Merck & Company, Inc. (new)

NYQ : MRK - 18 Aug, 4:00pm
-0.35 (-0.57%) After Hours:
Open 61.77 Mktcap 167.71B
High 61.81 52wk Hight 66.80
Low 61.16 52wk Low 58.29
Vol 8.42M Avg Vol 8.28M
Eps 3.87 P/e 33.29
Currency: USD

Johnson & Johnson

NYQ : JNJ - 18 Aug, 4:01pm
-0.41 (-0.31%) After Hours:
Open 132.67 Mktcap 355.98B
High 133.78 52wk Hight 137.08
Low 132.38 52wk Low 109.32
Vol 4.79M Avg Vol 5.57M
Eps 7.18 P/e 22.44
Currency: USD

Pfizer, Inc.

NYQ : PFE - 18 Aug, 4:00pm
-0.28 (-0.85%) After Hours:
Open 32.91 Mktcap 194.30B
High 32.97 52wk Hight 35.38
Low 32.65 52wk Low 29.83
Vol 15.49M Avg Vol 18.62M
Eps 2.56 P/e 23.90
Currency: USD

Direxion Daily 10-Yr Treasury B

PCX : TYO - 18 Aug, 3:59pm
+0.00 (+0.00%) After Hours:
Open 13.55 Mktcap
High 13.66 52wk Hight 16.29
Low 13.55 52wk Low 12.79
Vol 2558 Avg Vol 4389
Eps P/e
Currency: USD
Sign up via our free email subscription service to receive notifications when new information is available.

The Mundipharma network of independent associated companies announced that it has acquired from CellAct the worldwide development, commercialization and manufacturing rights to CAP7.1.

Bristol-Myers Squibb Company and IFM Therapeutics announced that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of IFM Therapeutics, a venture-backed biotech company focused on developing therapies that modulate novel targets in the innate immune system to treat cancer, autoimmunity and inflammatory disorders.


TraceLink Inc., the World’s Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, today announced financial and company results for the second quarter of 2017.

A method of testing drugs thatprompt the immune system to attack and destroy cancer cells has been developed which can speed up drug discovering andreducethe unnecessary use of mice in drug screening programmes.

Orphan genetic diseases have become an increasingly popular area for drug development through a variety of novel mechanistictherapeutic approaches.

Automation in its broadest sense has expanded from its original industrial manufacturing base to laboratories and businesses.

KemPharm, Inc. , a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced preliminary results of KP415.109.

Selvita S.A. and The Leukemia & Lymphoma Society (LLS) announced a partnership to co-fund further preclinical and clinical development of a targeted therapy to treat patients with acute myeloid leukemia (AML).

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced that it is now actively enrolling patients in a global pivotal study of Aerucin®, the Company’s broadly reactive monoclonal antibody being developed to treat acute pneumonia caused by Gram-negative bacteria Pseudomonas aeruginosa.